Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.
Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, Alonso A, Sperling AS, Campbell T, Petrocca F, Hege K, Kaiser S, Loiseau HA, Anderson KC, Munshi NC. · 2021
Read Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. by Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, Alonso A, Sperling AS, Campbell T, Petrocca F, Hege K, Kaiser S, Loiseau HA, Anderson KC, Munshi NC. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7870932.txt.
Description
Samur and co-authors trace how one myeloma patient beat CAR T therapy by losing its target. BCMA-directed CAR T cells give deep responses in myeloma. Relapse after treatment is common, though. Its causes were ill-defined. The team followed one patient over time.
Single-cell gene checks compared samples before and after relapse. A cancer clone lost both copies of the BCMA gene. One copy was deleted outright. The other carried a stop-making mutation. Without BCMA, the second cell dose could not expand. Blood levels of loose BCMA vanished as well. The case warns teams to test the target gene at relapse. Loss of the bullseye can defeat the whole therapy.
Catalog record
| CREATOR | Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, Alonso A, Sperling AS, Campbell T, Petrocca F, Hege K, Kaiser S, Loiseau HA, Anderson KC, Munshi NC. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |